Cargando…

Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus

Impaired health-related quality of life (HRQoL) is a major problem in patients with systemic lupus erythematosus (SLE). Antimalarial agents (AMA) are the cornerstone of SLE therapy, but data on their impact on HRQoL are scarce. We investigated this impact using baseline data from the BLISS-52 (NCT00...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomez, Alvaro, Soukka, Sofia, Johansson, Petter, Åkerström, Emil, Emamikia, Sharzad, Enman, Yvonne, Chatzidionysiou, Katerina, Parodis, Ioannis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355692/ https://www.ncbi.nlm.nih.gov/pubmed/32532059 http://dx.doi.org/10.3390/jcm9061813

Ejemplares similares

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2019)

Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2020)

How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study
por: Emamikia, Sharzad, et al.
Publicado: (2022)

Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2021)

Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus
por: Borg, Alexander, et al.
Publicado: (2023)

Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
por: Emamikia, Sharzad, et al.
Publicado: (2022)

EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus
por: Lindblom, Julius, et al.
Publicado: (2022)

EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
por: Lindblom, Julius, et al.
Publicado: (2021)

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
por: Gomez, Alvaro, et al.
Publicado: (2023)

Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State
por: Hua, Nicole, et al.
Publicado: (2023)

Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE
por: Borg, Alexander, et al.
Publicado: (2021)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Lupus Erythematosus Panniculitis in Pregnancy and Antimalarials
por: Srivastava, Ankita
Publicado: (2016)

Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver’s Seat in Their Disease Monitoring?
por: Parodis, Ioannis, et al.
Publicado: (2022)

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
por: Emamikia, Sharzad, et al.
Publicado: (2016)

Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
por: Sjöwall, Christopher, et al.
Publicado: (2022)

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
por: Nikolopoulos, Dionysis, et al.
Publicado: (2023)

B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
por: Parodis, Ioannis, et al.
Publicado: (2020)

B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools
por: Parodis, Ioannis, et al.
Publicado: (2022)

Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management
por: Dey, Mrinalini, et al.
Publicado: (2021)

Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade
por: Lindblom, Julius, et al.
Publicado: (2022)

Intracardiac Thrombi in Morbus Adamantiades–Behçet in Two Swedish Patients
por: Da Mutten, Raffaele, et al.
Publicado: (2023)

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
por: Giannakou, Ioanna, et al.
Publicado: (2018)

Successful treatment of a child’s lupus erythematosus tumidus with antimalarials
por: Arasiewicz, Hubert, et al.
Publicado: (2023)

Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey
por: Petitdemange, Arthur, et al.
Publicado: (2021)

Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2022)

Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
por: Parodis, Ioannis, et al.
Publicado: (2023)

COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
por: Giannopoulou, Nefeli, et al.
Publicado: (2023)

Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

Systemic Lupus Erythematosus: Definitions, Contexts, Conflicts, Enigmas
por: Rekvig, Ole Petter
Publicado: (2018)

Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus
por: Adamichou, Christina, et al.
Publicado: (2020)

Interferon (IFN)-λ is a potential mediator in lupus nephritis
por: Zickert, Agneta, et al.
Publicado: (2016)

Systemic Lupus Erythematosus May Be a Risk Factor for Antimalarial‐Induced Retinopathy Compared With Other Rheumatologic Diseases
por: Liu, Hsin Yen, et al.
Publicado: (2023)

Prediction of prognosis and renal outcome in lupus nephritis
por: Parodis, Ioannis, et al.
Publicado: (2020)

Extracellular Vesicles as Therapeutic Agents in Systemic Lupus Erythematosus
por: Perez-Hernandez, Javier, et al.
Publicado: (2017)

ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis
por: Tao, Chen-Yang, et al.
Publicado: (2019)

Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis
por: Becker-Merok, Andrea, et al.
Publicado: (2006)

Vascular Disease in Systemic Lupus Erythematosus
por: Pyrpasopoulou, Athina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_f7dtov2fjrjc11iovnbfd1640p